Gastritis, dyspepsia and peptic ulcer disease

Minerva Medica

Volumn 99, Issue 3, 2008, Pages 323-333

  Dore, M P ^a   Graham, D Y ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anti inflammatory agents, non steroidal; Gastritis, atrophic; Helicobacter pylori

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMOXICILLIN; BISMUTH; CALCIUM; CLARITHROMYCIN; FURAZOLIDONE; IBUPROFEN; IRON; METRONIDAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

AGE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DRUG MEGADOSE; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PEPTIC ULCER; PEPTIC ULCER BLEEDING; REVIEW; STOMACH INJURY; STOMACH ULCER; SYMPTOMATOLOGY;

DYSPEPSIA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 46449108600     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007;132:2320-7.
2. Faber K. Gastritis and its consequences. New York: Oxford University Press; 1935.
3. Dore MP, Graham DY. Pathogenesis of duodenal ulcer disease: the rest of the story. Baillieres Best Pract Res Clin Gastroenterol 2000;14:97-107.
4. Graham DY, Dore MP. Perturbations in gastric physiology in Helicobacter pylori duodenal ulcer: are they all epiphenomena? Helicobacter1997;(2 Suppl 1):S44-9.
5. Faber K. Chronic gastritis: its relation to achylia and ulcer. Lancet 1927;2:902-7.
6. Faber K. Gastritis and its consequences. Paris: Oxford University Press; 1935.
7. Wood IJ, Taft LI. Diffuse lesions of the stomach: An account with special reference to the value of gastric biopsy. London: Edward Arnold; 1958.
8. Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 2007;102:1101-7.
9. Graham DY. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol 1991;6:105-13.
10. Graham DY, Malaty HM, Evans DG, Evans DJ, Jr. Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991;100:1495-501.
11. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994;35:742-5.
12. Malaty HM, Evans DG, Evans DJ Jr, Graham DY. Helicobacter pylori in Hispanics: comparison with blacks and whites of similar age and socioeconomic class. Gastroenterology 1992;103:813-6.
13. Breuer T, Malaty HM, Graham DY. The epidemiology of Helicobacter pylori-associated gastroduodenal diseases. In: Ernst P, Michetti P, Smith PD, editors. The immunobiology of Helicobacter pylori from pathogenesis to prevention. Philadelphia: Lippincott-Raven; 1997. p. 1-14.
14. Dixon MF. Helicobacter pylori and peptic ulceration: histopathological aspects. J Gastroenterol Hepatol 1991;6:125-30.
15. Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 1996;31:546-50.
16. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996;156:2321-32.
17. Koch M. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol. Ital J Gastroenterol Hepatol1999;31(Suppl 1):S54-62.
18. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
19. Hawkey CJ, Weinstein WM, Smalley W, Gitton X, Sallstig P, Stricker K et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology 2007;133:57-64.
20. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E et al. Comparison of lumiracoxib with naproxen and Ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
21. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81.
22. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
23. Varis K, Ihamaki T, Harkonen M, Samloff IM, Siurala M. Gastric morphology, function, and immunology in first-degree relatives of probands with pernicious anemia and controls. Scand J Gastroenterol 1979;14:129-39-
24. Centanni M, Marignani M, Gargano L, Corleto VD, Casini A, Delle Fave G et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch Intern Med 1999;159:1726-30.
25. Negrini R, Savio A, Poiesi C, Appelmelk BJ, Buffoli F, Paterlini A et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 1996;111:655-65.
26. Annibale B, Marignani M, Azzoni C, D'Ambra G, Caruana P, D'Adda T et al. Atrophic body gastritis: distinct features associated with Helicobacter pylori infection. Helicobacter 1997;2:57-64.
27. Strickland RG, MacKay IR. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis 1973;18:426-40.
28. Tack J, Talley NJ, Camilleri M , Holtmann G, Hu P, Malagelada JR, Stanghellini V. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-79.
29. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80.
30. Heikkinen M, Pikkarainen P, Eskelinen M, Julkunen R. GPs' ability to diagnose dyspepsia based only on physical examination and patient history. Scand J Prim Health Care 2000;18:99-104.
31. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;(9 Suppl 2):59-69.
32. Ihamaki T, Varis K, Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Comparison with a computer-matched family sample. Scand J Gastroenterol 1979;14:801-12.
33. Akdamar K, Ertan A, Agarwal NM, Mc Mahon FG, Ryan J. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc 1986;32:78-80.
34. Anand BS, Raed AK, Malaty HM, Genta RM, Klein PD, Evans DJ Jr et al. Low point prevalence of peptic ulcer in normal individuals with Helicobacter pylori infection. Am J Gastroenterol 1996;91:1112-5.
35. Johnsen R, Bernersen B, Straume B, Forde OH, Bostad L, Burhol PG. Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. Br Med J 1991;302:749-52.
36. Hilton D, Iman N, Burke GJ, Moore A, O'Mara G, Signorini D et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001;96:380-4.
37. Sjodin I, Svedlund J, Dotevall G, Gillberg R. Symptom profiles in chronic peptic ulcer disease. A detailed study of abdominal and mental symptoms. Scand J Gastroenterol 1985;20:419-27.
38. Westbrook JI, McIntosh JH, Duggan JM. Accuracy of provisional diagnoses of dyspepsia in patients undergoing first endoscopy. Gastrointest Endosc 2001;53:283-8.
39. Soil AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307-19.
40. Wallace MB, Durkalski VL, Vaughan J, Palesch YY, Libby ED, Jowell PS et al. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. Gut 2001;49:29-34.
41. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
42. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-71.
43. Wotherspoon AC, Ortiz-Hidalgo C, Falzon M, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-6.
44. Price AB. The Sydney System: histological division. J Gastroenterol Hepatol 1991;6:209-22.
45. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
46. Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;56:631-6.
47. Sepulveda AR, Dore MP, Bazzoli F. Chronic gastritis. In: eMedicine-gastroenterology. [Internet] Available from http://www.emedicine.com/ med/topic852.htm. Last Access Sep 2007, [cited October 15, 2007].
48. Sepulveda AR. Molecular testing of Helicobacter pylori-associated chronic gastritis and premalignant gastric lesions: clinical implications. J Clin Gastroenterol 2001;32:377-82.
49. Graham DY, Opekun AR, Yamaoka Y, Osato MS, el-Zimaity HM. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 2003;17:193-200.
50. Kasirga E, Coker I, Aydogdu S, Ya ci R, Taneli B, Gousseinov A. Increased gastric juice leukotriene B4, C4 and E4 concentrations in children with Helicobacter pylori colonization. Turk J Pediatr 1999;41:335-9.
51. Wilson KT, Crabtree JE. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007;133:288-308.
52. D'Elios MM, Amedei A, Manghetti M, Costa F, Baldari CT, Quazi AS et al. Impaired T-cell regulation of B-cell growth in helicobacter pylori- related gastric low-grade MALT lymphoma. Gastroenterology 1999;117:1105-12.
53. Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E et al. Molecular analysis of the progression from Helicobacter pylori- associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998;338:804-10.
54. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7.
55. Weber DM, Dimopoulos MA, Anandu DP, Pugh WC, Steinbach G. Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology 1994;107:1835-8.
56. Roggero E, Zucca E, Pinotti G, Capella C, Savio A, Pedrinis E et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995;122:767-9.
57. Franco L, Talamini G, Carra G, Doria D. Expression of COX-1, COX-2, and inducible nitric oxide synthase protein in human gastric antrum with Helicobacter pylori infection. Prostaglandins Other Lipid Mediat 1999;58:9-17.
58. Wallace JL. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001;15:691-703.
59. Kitahora T, Guth PH. Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation. Gastroenterology1987;93:810-7.
60. Asako H, Kubes P, Wallace J, Wolf RE, Granger DN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 1992;103:146-52.
61. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34.
62. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
63. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
64. DeNardi FG, Riddell RH. Reactive (chemical) gastropathy and gastritis. In: Graham DY, Genta RM, Dixon MF, editors. Gastritis. Philadelphia: Lipincott Williams &Wilkins, 1999. p. 97-107.
65. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
66. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-7.
67. Catalano F, Branciforte G, Catanzaro R, Cipolla R, Bentivegna C, Brogna A. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. Aliment Pharmacol Ther 2000;14:1329-34.
68. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication. Helicobacter 2001;6:157-162.
69. Nagahara A, Miwa H, Ogawa K, Kurosawa A, Ohkura R, Iida N et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000;5: 88-93.
70. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective man 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001;15:417-21.
71. Neville PM, Everett S, Langworthy H, Tompkins D, Mapstone NP, Axon AT et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999;13:497-501.
72. Okada M, Oki K, Shirotani T, Seo M, Okabe N, Maeda K et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 1998;33:640-5.
73. Okada M, Nishimura H, Kawashima M, Okabe N, Maeda K, Seo M et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 1999;13:769-74.
74. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/ omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998;3:54-8.
75. Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002;162:153-60.
76. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
77. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001;11:341-8.
78. Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M et al. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003;50:2274-8.
79. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002;50:378-81.
80. Graham DY, Uemura N. Natural history of gastric cancer after Helicobacter pylori eradication in Japan: after endoscopic resection, after treatment of the general population, and naturally. Helicobacter 2006;11:139-43.